Express Scripts is suing the Federal Trade Commission (FTC), demanding the retraction of a report it claims is false and harmful to the pharmacy benefit manager (PBM) industry. Express Scripts is ...

On Tuesday, the healthcare company’s PBM, Express Scripts, sued the Federal Trade Commission ... The lawsuit asks a federal judge to order the FTC to withdraw the report, and recuse FTC Chair ...

Express Scripts, one of the country’s largest pharmacy benefit managers, sued the Federal Trade Commission (FTC) Tuesday and demanded the agency retract a report saying the industry middlemen ...

Express Scripts, Inc. sued the Federal Trade Commission on Tuesday ... a subsidiary of The Cigna Group, is demanding the FTC retract a report it made in July 2024 that said the pharmacy benefit ...

The FTC may be gearing up to sue Express Scripts, CVS Caremark and OptumRx based on its investigation, Bloomberg News reported in July, citing a source familiar with the matter. Express Scripts ...

including Express Scripts, that use their market power to overcharge patients. "The FTC has taken unconstitutional actions in ...

NEW YORK, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade ... middlemen raise drug costs defamatory. The FTC said in the July report that market ...

"Express Scripts sues FTC and demands drug pricing report retraction" was originally created and published by Pharmaceutical ...

Cigna's Express Scripts, one of the country's largest pharmacy benefit managers, today sued the Federal Trade ... bringing drug costs down." Related: FTC staff objects to big PBMs' 'outsized ...

For more than two years, Express Scripts fully cooperated with the FTC study into the PBM industry, meeting the agency's extensive demands for data and information. The FTC's report disregarded ...

Express Scripts, Inc. (“Express Scripts”), one of the largest pharmacy benefit managers (PBMs) in the United States, ...

Express Scripts, one of the largest pharmacy benefit ... The lawsuit also alleged the FTC “followed prejudice and politics, not evidence or sound economics, and wrongly concluded that PBMs ...